TLDR
The All-In Podcast hosts discuss OpenAI missing user and revenue targets while advancing product releases like GPT-5.5, the Elon Musk vs. OpenAI lawsuit over charitable trust breach, massive Big Tech CapEx spending ($725B in 2026) on AI infrastructure, promising phase 3 trial results for retatrutide (a triple-agonist weight-loss drug), and David Friedberg's firsthand experience attending Supreme Court oral arguments in the Monsanto Roundup case. The episode highlights the intense competition in AI, the shift to asset-heavy infrastructure investment, and the intersection of law, science, and markets.
For you
PRO members can sign in and request more information — or their own version of this digest, tuned to what they care about.
Sign in to unlockSurprising Insights
OpenAI's $600B compute spend commitments roughly equal its current secondary market valuation, meaning the entire enterprise value is tied to future infrastructure spend.
Google Cloud grew 63% year-over-year on $20B quarterly revenue, making Google a co-leader in both consumer and enterprise AI alongside OpenAI.
The Supreme Court uses a double-door 'airlock' system for its private conferences, and justices rotate security positions every 20 minutes in a highly choreographed ritual.
Retatrutide's glucagon agonism shifts energy metabolism to favor fat burning over muscle loss, enabling rapid body recomposition — a potential 'upgrade' over semaglutide/tirzepatide.
Greg Brockman kept a detailed diary documenting OpenAI's strategy to oust Elon Musk and convert to for-profit, which David Sacks calls 'discovery maxing' — a legal liability goldmine.
Key takeaways
OpenAI missed its 1 billion weekly active user target and 2025 revenue goals, but GPT-5.5 shows strong product momentum, especially in coding, while Anthropic's Opus 4.7 faces compute constraints.
Elon Musk's lawsuit against OpenAI alleges breach of charitable trust; Greg Brockman's diary entries reveal internal discussions about converting to for-profit and removing Musk, creating a 'smoking gun' for discovery.
Google, Microsoft, Amazon, and Meta guided $725B in 2026 CapEx, driven by voracious AI compute demand; free cash flow is plummeting as hyperscalers prioritize infrastructure over shareholder returns.
Retatrutide (Lilly's triple-agonist) showed remarkable phase 3 results: 37 lb average weight loss, 80% liver fat reduction, 27% non-HDL cholesterol drop, and potential anti-inflammatory/anti-aging effects.
The Supreme Court's Monsanto case centers on federal preemption (EPA label authority) vs. state failure-to-warn laws; Friedberg describes the Court as a highly functional, sacred institution with a unique deliberative process.
Notable quotes
“If we make it okay to loot a charity, the entire foundation of charitable giving in America will be destroyed. That's my concern.”
▸ Notable quotes · 31:35“Everything in this market is power constrained. The reason that these folks may miss a number or a forecast have nothing to do with demand. It is entirely 100% due to the supply of the power necessary to generate the output token.”
▸ Notable quotes · 9:29“AI is now synonymous with the growth of the American economy. And if there's no economic growth, there's not going to be money to pay for all the social programs... All these things we want to spend money on. We have to have a vibrant economy. And that is now synonymous with AI.”
▸ Notable quotes · 51:01“You gave your AI permission to overwrite code in the internal file system? Were you going to tell me about this? No. I thought that was the company policy these days.”
▸ Notable quotes · 53:37Chapters
3:06 — OpenAI Misses Targets but Gains Product Momentum: Wall Street Journal reports OpenAI missed 1B user and revenue targets; $600B compute commitments equal valuation; CFO Sarah Friar vs. Sam Altman tension on IPO readiness; GPT-5.5 release impresses developers while Anthropic's Opus 4.7 struggles with compute gating.
31:07 — Elon Musk vs. OpenAI Lawsuit: Musk alleges breach of charitable trust, seeks $150B damages and reversion to non-profit; Greg Brockman's diary reveals explicit plans to remove Musk and convert to for-profit; bench trial before Obama-appointed Judge Rogers; Polymarket gives Musk 42% win probability.
41:03 — Big Tech Earnings & $725B CapEx Surge: Google, Microsoft, Amazon, Meta report strong cloud growth (Google Cloud +63% YoY) but massive CapEx guidance; free cash flow down 97% (Amazon), 12% (Google/Microsoft), 8% (Meta); Chamath predicts hyperscalers will become highly leveraged industrial firms; Sachs sees demand-driven validation of AI bull thesis.
59:00 — Retatrutide Phase 3 Results: Potential Wonder Drug: Lilly's triple-agonist (GLP-1/GIP/glucagon) shows 37 lb avg weight loss, 80% liver fat reduction, 27% non-HDL cholesterol drop, 41% triglyceride reduction, A1C from 7.9% to 6%; glucagon agonism favors fat over muscle loss; FDA approval projected mid-2027; fitness community excited for body recomposition.
67:00 — Friedberg's Supreme Court Experience: Monsanto Roundup Case: Friedberg attends oral arguments on federal preemption (EPA label authority) vs. state failure-to-warn laws; Bayer paid $10B in settlements, 90K cases pending; justices debate Chevron Doctrine overturn implications; Friedberg describes Court as sacred, highly functional institution with airlock deliberation room.
Speakers
Jason Calacanis (JCal) — Host, moderator, angel investor
David Friedberg — Host, CEO of Ohalo, venture investor
Chamath Palihapitiya — Host, CEO of Social Capital, venture investor
David Sacks — Host, CEO of Glue, venture investor, former PayPal COO